相关实验视频

Updated: Jul 12, 2025

Luminophore Formation in Various Conformations of Bovine Serum Albumin by Binding of GoldIII

Luminophore Formation in Various Conformations of Bovine Serum Albumin by Binding of GoldIII

Published on: August 31, 2018

与血清白蛋白复合的甲复合的复杂化研究

Hong Zhuang¹, Xiaoliang Zhang¹, Sijia Wu¹

¹College of Food Science and Engineering, Jilin University, Changchun, Jilin 130062, China.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

|October 23, 2023

概括

来自Hibiscus taiwanensis的Syringaldehyde (SA) 与牛血清白蛋白 (BSA) 相互作用,改变其结构并增强α-氨基酶抑制,用于治疗潜在的低血糖症,细胞毒性最小.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

甲 (SA) 是一种在台湾中发现的类聚,具有药理潜力.
对SA的研究有限,阻碍了其治疗应用.
了解SA与血清白蛋白等生物分子的相互作用对其发展至关重要.

研究的目的:

使用各种光谱和计算方法研究甲 (SA) 和牛血清白蛋白 (BSA) 之间的相互作用.
评估SA-BSA复杂化对α-氨基酶抑制的影响.
评估SA在BRL-3A细胞上的细胞毒性.

主要方法:

多光谱研究包括UV/Vis吸收和光谱学.
福利埃变换红外 (FT-IR) 光谱学用于分析二次结构变化.
计算生物学分析以确定结合点和相互作用.
使用BRL-3A细胞进行细胞毒性测定.

主要成果:

SA 结合会诱导 BSA 的形状变化,改变其二次结构.
SA与BSA形成复合体,导致光火.
计算分析显示了SA和BSA在活性部位之间的疏水相互作用.
SA对BRL-3A细胞具有微不足道的毒性.
与单独的SA相比,SA-BSA复合体表现出增强的α-氨酶抑制.

结论:

SA与BSA相互作用,导致显著的形状和结构变化.
由于其增强的α-氨基酶抑制活性,SA显示出治疗低血糖的潜力.
这项研究为进一步研究SA的治疗应用提供了基础.

关键词:

细胞毒性细胞毒性多光谱的多光谱的血清白蛋白是如何形成的甲注射器的使用方法

更多相关视频

Metabolic Glycoengineering of Sialic Acid Using N-acyl-modified Mannosamines

Metabolic Glycoengineering of Sialic Acid Using N-acyl-modified Mannosamines

Published on: November 25, 2017

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

Published on: June 27, 2011

相关概念视频

Drug Distribution: Plasma Protein Binding

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...